Academic Highlights: A Roadmap to Key Pharmacologic Principles in Using Antipsychotics in the Treatment of Older Patients
J Clin Psychiatry 2009;70(1):131-138
© Copyright 2015 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Antipsychotics are widely used to
treat psychiatric disorders in older
patients. While the growing number
of second-generation antipsychotics
(SGAs) has increased options for patients,
it has also complicated clinical
decision-making. Data from the
American Psychiatric Association’s
(APA’s) Practice Research Network
indicated disproportionately high use
of antipsychotics and benzodiazepine
medications among older patients compared
with those under age 65.